LNTH
Lantheus Holdings, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$100.61
−0.09%Price chart
Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3Nov 6
Key dataNov 6, 2026
Open$100.82
From 52W high−9.31%
Volume1.58M
Market cap$6.57B
P/E (TTM)24.3x
P/S (TTM)4.2x
Div yield—
Key dataNov 6, 2026
Open
$100.82
From 52W high
−9.31%
Volume
1.58M
Market cap
$6.57B
ValuationView details →
P/E (Fwd)
16.8x
EV/EBITDA
13.1x
P/E (TTM)
24.3x
RSI (14)
56.5
MomentumView details →
1D Return
−0.09%
YTD Return
+51.33%
SummaryUpdated Sep 1, 2026
Lantheus Holdings, Inc. (NASDAQ:LNTH) is a specialized pharmaceutical company founded in 1956 and headquartered in North Billerica, Massachusetts. The company develops, manufactures, and commercializes diagnostic and therapeutic radiopharmaceuticals that assist clinicians in diagnosing and treating heart disease, cancer, and other conditions. Originally focused on traditional nuclear medicine products, Lantheus has transformed into a leading player in the rapidly growing radiopharmaceutical oncology market, particularly through its blockbuster PSMA PET imaging agent PYLARIFY, which became the first radiopharmaceutical to exceed $1 billion in annual sales.
Similar companies
Latest newsMore news →
The Centers for Medicare & Medicaid Services (US) issued a CY2027 final rule maintaining separate payment for advanced diagnostic imaging agents and confirming PYLARIFY TruVu’s transitional pass-through status through September 30, 2029.2d agoLantheus Holdings reported third-quarter 2026 worldwide revenue of $389.9 million, GAAP diluted earnings per share of $0.33 and adjusted diluted earnings per share of $1.68.2d agoMultiple banks are competing to join a $4.25 billion debt financing for Curium US Holdings LLC’s acquisition of Lantheus Holdings, Inc., ahead of a planned syndication to investors next year.23d ago